Patent application number | Description | Published |
20080287837 | ULTRASOUND MEDICAL SYSTEM AND METHOD - An ultrasound medical system includes an interstitial end effector. The interstitial end effector is interstitially insertable into patient tissue, includes at least one medical-treatment ultrasound transducer, and includes at least one end-effector-tissue-track ablation device. One method for ultrasonically treating a lesion in a patient includes the steps of obtaining the interstitial end effector and inserting it into the patient creating a tissue track which is surrounded by patient tissue and which ends at the distal end of the inserted interstitial end effector. Other steps include ultrasonically ablating the lesion using the at-least-one medical-treatment ultrasound transducer, using the at-least-one end-effector-tissue-track ablation device to ablate the patient tissue surrounding the tissue track along substantially the entire tissue track, and withdrawing the end effector from the patient. | 11-20-2008 |
20090198156 | ULTRASOUND MEDICAL TREATMENT SYSTEM AND METHOD - An ultrasound medical treatment system includes an ultrasound medical treatment transducer and a controller. Methods of the invention so control the medical treatment transducer. In one arrangement, the controller movingly controls the medical treatment transducer to emit ultrasound to thermally ablate patient tissue: 1) for a plurality of predetermined time intervals each associated with the medical treatment transducer movingly disposed at a different one of an equal number of predetermined positions, wherein a next-in-time time interval is associated with a position which is spatially non-adjacent to a position associated with a present-in-time time interval; or 2) for a predetermined time interval during which the transducer is continuously moved. In another arrangement, the transducer has an array of transducer elements and the controller activates different non-overlapping groups or different overlapping groups of transducer elements at different times. | 08-06-2009 |
20100312150 | SYSTEM AND METHOD FOR MEDICAL TREATMENT USING ULTRASOUND - A system and method for medical treatment of tissue using ultrasound. The system comprises a probe having an array of transducer elements, an ultrasound waveform generator adapted to generate at least one electrical ultrasound signal, and a plurality of phase controls, each coupled to the ultrasound waveform generator and adapted to generate from the electrical ultrasound signal a phase-shifted drive signal that is coupled to an associated transducer element. The drive signal is effective to control grating lobe foci emitted by the array. The method employs the system. | 12-09-2010 |
20110040184 | METHOD FOR MONITORING OF MEDICAL TREATMENT USING PULSE-ECHO ULTRASOUND - A method for ultrasound imaging of anatomical tissue. A first signal is received from a first imaging ultrasound wave which has been reflected from a location in the anatomical tissue during a first time period. A second signal is received from a second imaging ultrasound wave which has been reflected from the location in the anatomical tissue during a later second time period, following a discrete medical treatment. The second signal is subtracted from the first signal to form a difference signal. The difference signal may be scaled, spatially filtered, then used to generate an indication, the indication showing the effect of the medical treatment in the location in the anatomical tissue. | 02-17-2011 |
20110201975 | ULTRASOUND MEDICAL SYSTEM - An ultrasound medical system includes an ultrasound end effector and at least one non-ultrasound tissue-property-measuring sensor. The ultrasound end effector includes a medical ultrasound transducer assembly having at least one medical-treatment ultrasound transducer. The at-least-one non-ultrasound tissue-property-measuring sensor is supported by the ultrasound end effector and is positionable in contact with patient tissue. | 08-18-2011 |
20130218013 | Ultrasound Medical System and Method - An ultrasound medical system includes an interstitial end effector. The interstitial end effector is interstitially insertable into patient tissue, includes at least one medical-treatment ultrasound transducer, and includes at least one end-effector-tissue-track ablation device. One method for ultrasonically treating a lesion in a patient includes the steps of obtaining the interstitial end effector and inserting it into the patient creating a tissue track which is surrounded by patient tissue and which ends at the distal end of the inserted interstitial end effector. Other steps include ultrasonically ablating the lesion using the at-least-one medical-treatment ultrasound transducer, using the at-least-one end-effector-tissue-track ablation device to ablate the patient tissue surrounding the tissue track along substantially the entire tissue track, and withdrawing the end effector from the patient. | 08-22-2013 |
20140323864 | Medical System Having an Ultrasound Source and an Acoustic Coupling Medium - An ultrasound medical system has an end effector including a medical ultrasound transducer and an acoustic coupling medium. The acoustic coupling medium has a transducer-proximal surface and a transducer-distal surface. The medical ultrasound transducer is positioned to emit medical ultrasound through the acoustic coupling medium from the transducer-proximal surface to the transducer-distal surface. The end effector is adapted to change a property (such as the shape and/or the temperature) of the acoustic coupling medium during emission, and/or between emissions, of medical ultrasound from the medical ultrasound transducer during a medical procedure on a patient. In one example, such changes are used to change the focus and/or beam angle of the emitted ultrasound during the medical procedure. | 10-30-2014 |
Patent application number | Description | Published |
20080275106 | Anticancer and Antiprotozoal Dihydroartemisinene and Dihydroartemisitene Dimers with Desirable Chemical Functionalities - This invention comprises compositions containing dihydroartemisinin- and dihydroartemisitene-dimers with activity as anticancer or anticancer metastasis agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer or prevention of cancer metastasis, and protozoal infections, including malaria, or leishmaniasis. The compounds of this invention represent a potential new class of anti-tumor or anti-metastasis agents, one that has shown promising activity against solid tumors. | 11-06-2008 |
20080287658 | Docetaxel Immunoassay - Novel conjugates of docetaxel and novel docetaxel immunogens derived from the 7 and 10 positions of docetaxel and monoclonal antibodies generated by these docetaxel linked immunogens are useful in immunoassays for the quantification and monitoring of docetaxel in biological fluids. | 11-20-2008 |
20090221786 | Taxol immunoassay - Novel conjugates of taxol and novel taxol immunogens derived from the 9 and 7 positions of taxol and monoclonal antibodies generated by these taxol linked immunogens are useful in immunoassays for the quantification and monitoring of taxol in biological fluids. | 09-03-2009 |
20110086900 | COMPOSITIONS FOR PREVENTION/PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS - The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I) Tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a composition containing at least one water soluble urushiol ester compound. | 04-14-2011 |
20110275555 | COMPOSITIONS CONTAINING DELTA-9-THC-AMINO ACID ESTERS AND PROCESS OF PREPARATION - Compositions of the formulae (I), (II) and (III); where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof. Methods of preparation of these compositions and methods of treating any disease condition responsive to THC comprising administration of at least one these compositions in a pharmaceutically acceptable carrier using a pharmaceutically acceptable formulation. | 11-10-2011 |
20130303582 | COMPOSITIONS FOR PREVENTION/PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS - The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I) | 11-14-2013 |
20150045282 | COMPOSITIONS CONTAINING DELTA-9-THC-AMINO ACID ESTERS AND PROCESS OF PREPARATION - Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof. | 02-12-2015 |
20150202176 | Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis - The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I) | 07-23-2015 |
Patent application number | Description | Published |
20110154076 | TIME NEGOTIATION USING SERIAL VOLTAGE IDENTIFICATION COMMUNICATION - According to some embodiments, a method and system are provided to initiate communication at an integrated circuit that is electrically coupled to a plurality of voltage regulators, determine a slowest one of the plurality of voltage regulators that is electrically coupled to the integrated circuit, and communicate with the plurality of voltage regulators that are electrically coupled to the integrated circuit at a speed associated with the slowest one of the plurality of voltage regulators. | 06-23-2011 |
20140281695 | PROCESSOR HANG DETECTION AND RECOVERY - Various aspects provide forced halt functionality for a processor to facilitate troubleshooting of processor hang situations. In the event that the processor initiates a transaction that does not receive a completion acknowledgement, halt detection logic can initiate a forced halt sequence that causes the processor to abort all pending transactions and transition to a debug state so that the internal state of the processor can be viewed. In addition, the processor can maintain a record of the processor state at the time that the hung transaction was dispatched, which can be viewed during debug mode to facilitate determining a cause of the hung transaction. | 09-18-2014 |
20140281722 | DEBUGGING PROCESSOR HANG SITUATIONS USING AN EXTERNAL PIN - Various aspects provide forced halt functionality for a processor to facilitate troubleshooting of processor hang situations. In the event that the processor initiates a transaction that does not receive a completion acknowledgement, a forced halt sequence can be initiated, which causes the processor to abort all pending transactions and transition to a debug state so that the internal state of the processor can be viewed. In addition, the processor can maintain a record of the processor state at the time that the hung transaction was dispatched, which can be viewed during debug mode to facilitate determining a cause of the hung transaction. | 09-18-2014 |